CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novagali Pharma SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novagali Pharma SA
1 rue Pierre Fontaine Genavenir IV
Phone: + 33 1 69 87 40 20p:+ 33 1 69 87 40 20 Evry cedex, F-91058  France Ticker: NOVANOVA
This company was Merged or Acquired on 10/11/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Novagali Pharma SA is a France-based biopharmaceutical company engaged in the development of ophthalmologic products. The Company's products, at various stage of development, address diseases encountered at three different segment levels of the eye (surface, anterior and posterior segments), such as dry eye, allergy, anterior uveitis, glaucoma and retinopathies, among others. Their formulations are based on the Company's technology platforms: Novasorb and Eyeject. Novasorb is a cationic emulsion developed to address the challenges of topical ocular drug administration: absorption, drug solubility, patient compliance and high tolerability. Eyeject has been designed to offer a minimally-invasive approach to administer active compounds to the back of the eye. Novagali Pharma SA's range of products includes Cationorm, dedicated to the treatment of dry eye symptoms and marketed in certain European countries, South-East Asia and Middle-East.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201112/31/2010Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board AlainMunoz 9/30/2003 9/30/2003
Chairman of the Management Board, Member of the Executive Committee JeromeMartinez 50 3/23/2004 12/1/2003
Independent Vice Chairman of the Supervisory Board GeorgeLasezkay 59 11/18/2005 11/18/2005
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 42 (As of 6/30/2011)
Outstanding Shares: 16,274,532 (As of 6/30/2011)
Stock Exchange: BER
Fax Number: + 33 1 69 87 40 30
Email Address: contact@novagali.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023